

Anne C Chiang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3406442/publications.pdf>

Version: 2024-02-01

30
papers

1,664
citations

567281

15
h-index

580821

25
g-index

31
all docs

31
docs citations

31
times ranked

3339
citing authors

#	ARTICLE	IF	CITATIONS
1	COVID-19 and Cancer Center Operations: Lessons Learned From the NCCN Best Practices Committee. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, , 1-4.	4.9	2
2	Pre-Treatment Staging Imaging in Rectal Cancer: Results From the Quality Oncology Practice Initiative. <i>JCO Oncology Practice</i> , 2022, , OP2100455.	2.9	0
3	Relationship Between Participation in ASCO's Quality Oncology Practice Initiative Program and American Board of Internal Medicine's Maintenance of Certification Program. <i>JCO Oncology Practice</i> , 2022, , OP2100777.	2.9	0
4	Hematology/Oncology Fellowship Programs' Participation in the Quality Oncology Practice Initiative. <i>JCO Oncology Practice</i> , 2022, , OP2100807.	2.9	0
5	Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses. <i>Journal of Thoracic Oncology</i> , 2020, 15, 274-287.	1.1	95
6	Frontline immunotherapy for NSCLC – the tale of the tail. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 73-74.	27.6	35
7	Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 655-663.	10.7	335
8	Clinical Activity and Safety of Atezolizumab in a Phase 1 Study of Patients With Relapsed/Refractory Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2020, 21, 455-463.e4.	2.6	13
9	EGFR mutation testing and treatment decisions in patients progressing on first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors. <i>BMC Cancer</i> , 2020, 20, 356.	2.6	33
10	Phase I study of AMG 757, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting DLL3, in patients with small cell lung cancer (SCLC).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS9080-TPS9080.	1.6	5
11	Comparison of Survival Rates After a Combination of Local Treatment and Systemic Therapy vs Systemic Therapy Alone for Treatment of Stage IV Non-Small Cell Lung Cancer. <i>JAMA Network Open</i> , 2019, 2, e199702.	5.9	34
12	Monitoring InBaskets With Feedback to Providers Enhances the Timeliness of Patient Care. <i>Journal of Oncology Practice</i> , 2018, 14, e310-e315.	2.5	0
13	Measuring the Impact of Academic Cancer Network Development on Clinical Integration, Quality of Care, and Patient Satisfaction. <i>Journal of Oncology Practice</i> , 2018, 14, e823-e833.	2.5	11
14	Survival Rates after Thermal Ablation versus Stereotactic Radiation Therapy for Stage I Non-Small Cell Lung Cancer: A National Cancer Database Study. <i>Radiology</i> , 2018, 289, 862-870.	7.3	66
15	Association of Broad-Based Genomic Sequencing With Survival Among Patients With Advanced Non-Small Cell Lung Cancer in the Community Oncology Setting. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 469.	7.4	110
16	Speed of Adoption of Immune Checkpoint Inhibitors of Programmed Cell Death 1 Protein and Comparison of Patient Ages in Clinical Practice vs Pivotal Clinical Trials. <i>JAMA Oncology</i> , 2018, 4, e180798.	7.1	86
17	Durability of brain metastasis response and overall survival in patients with non-small cell lung cancer (NSCLC) treated with pembrolizumab.. <i>Journal of Clinical Oncology</i> , 2018, 36, 2009-2009.	1.6	33
18	Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer. <i>Cancer Discovery</i> , 2017, 7, 1420-1435.	9.4	507

#	ARTICLE	IF	CITATIONS
19	Establishing a Core Set of Performance Measures to Improve Value in Cancer Care: ASCO Consensus Conference Recommendation Report. <i>Journal of Oncology Practice</i> , 2017, 13, 135-140.	2.5	7
20	Why the Quality Oncology Practice Initiative Matters: It's Not Just About Cost. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, e102-e107.	3.8	6
21	Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy. <i>JAAD Case Reports</i> , 2016, 2, 264-268.	0.8	86
22	Possible Interaction of Anti-PD-1 Therapy with the Effects of Radiosurgery on Brain Metastases. <i>Cancer Immunology Research</i> , 2016, 4, 481-487.	3.4	49
23	ASCO PRO workgroup update: Patient-reported outcome measures as a quality indicator.. <i>Journal of Clinical Oncology</i> , 2016, 34, 276-276.	1.6	5
24	Multidisciplinary process improvement to optimize oral chemotherapy safety.. <i>Journal of Clinical Oncology</i> , 2016, 34, 134-134.	1.6	1
25	Incorporating Patient-Reported Outcomes to Improve Emotional Distress Screening and Assessment in an Ambulatory Oncology Clinic. <i>Journal of Oncology Practice</i> , 2015, 11, 219-222.	2.5	26
26	Final results of phase Ib of tarextumab (TRXT, OMP-59R5, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 7508-7508.	1.6	13
27	Activity and safety of pembrolizumab in patients with metastatic non-small cell lung cancer with untreated brain metastases.. <i>Journal of Clinical Oncology</i> , 2015, 33, 8035-8035.	1.6	24
28	Patient-Reported Outcome Performance Measures in Oncology. <i>Journal of Oncology Practice</i> , 2014, 10, 209-211.	2.5	79
29	Development of Smilow's EPIC ambulatory dashboard and the impact on bar code scanning compliance at care centers.. <i>Journal of Clinical Oncology</i> , 2014, 32, 166-166.	1.6	0
30	Characterization of aggressive interventions within 30 days of death in lung cancer patients at Smilow Cancer Hospital (SCH).. <i>Journal of Clinical Oncology</i> , 2014, 32, 20-20.	1.6	1